Federal Register / Vol. 77, No. 72 / Friday, April 13, 2012 / Notices 22333 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: April 9, 2012. 

Anna P. Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–8943 Filed 4–12–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Development of Oncolytic 

Viral Cancer Therapies 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in the following U.S. Patents 

to Jennerex Biotherapeutics 

(‘‘Jennerex’’) located in San Francisco, 

CA, USA. 

Intellectual Property: 

1. U.S. Patent No. 7,045,313 issued 

May 16, 2006 entitled, ‘‘Recombinant 

Vaccinia Virus Containing a Chimeric 

Gene Having Foreign DNA Flanked by 

Vaccinia Regulatory DNA’’ [HHS Ref. 

No. E–552–1982/2–US–03]; 

2. U.S. Patent No. 7,015,024 issued 

March 21, 2006 entitled, ‘‘Compositions 

Containing Recombinant Poxviruses 

Having Foreign DNA Expressed under 

the Control of Poxvirus Regulatory 

Sequence’’ [HHS Ref. No. E–552–1982/ 

2–US–04]; 

3. U.S. Patent No. 7,045,136 issued 

May 16, 2006 entitled, ‘‘Methods of 

Immunization Using Recombinant 

Poxviruses Having Foreign DNA 

Expressed under the Control of Poxvirus 

Regulatory Sequence’’ [HHS Ref. No. E– 

552–1982/2–US–05]; and 

4. U.S. Patent No. 6,998,252 issued 

February 14, 2006 entitled, 

‘‘Recombinant Poxviruses Having 

Foreign DNA Expressed under the 

Control of Poxvirus Regulatory 

Sequence’’ [HHS Ref. No. E–552–1982/ 

2–US–06]. 

The patent rights in these inventions 

have been assigned to the United States 

of America. 

The prospective exclusive license 

territory may be the U.S. and the field 

of use may be the ‘‘development and use 

of Licensed Patent Rights in 

combination with Licensee’s proprietary 

or in-licensed technologies for the 

treatment of human cancers’’. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before May 

14, 2012 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Jennifer Wong, Senior 

Licensing and Patenting Manager, 

Cancer Branch, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–4633; Facsimile: (301) 402– 

0220; Email: wongje@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

instant technology relates to 

recombinant poxviruses, and in 

particular the vaccinia virus, as a 

backbone that carries a foreign DNA. 

The virus has been modified by 

inserting a chimeric gene containing 

foreign DNA adjacent to poxvirus 

transcriptional regulatory sequence. The 

recombinant virus is subsequently 

transfected into a host and the foreign 

gene is expressed. For example, the 

foreign DNA can be related to a viral 

pathogen, tumor-associated antigen, or 

therapeutic transgenes. Upon 

administration of the recombinant virus 

to a human or animal subject, the 

foreign gene is expressed in vivo to elicit 

an immune response or express the 

therapeutic genes. The technology takes 

advantage of the unique properties of 

poxviruses as a delivering vehicle and 

of the ease of preparation of such 

constructs. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR Part 404.7. The 

prospective exclusive license may be 

granted unless within thirty (30) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR Part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: April 10, 2012. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2012–8891 Filed 4–12–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Citizenship and Immigration 

Services 

Agency Information Collection 

Activities: USCIS Case Status Online, 

Extension of a Currently Approved 

Information Collection; Comment 

Request 

ACTION: 30-Day notice of information 

collection under review: USCIS case 

status online. 

The Department of Homeland 

Security, U.S. Citizenship and 

Immigration Services (USCIS) is 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and clearance in accordance 

with the Paperwork Reduction Act of 

1995. The information collection was 

previously published in the Federal 

Register on January 30, 2012, at 77 FR 

4574, allowing for a 60-day public 

comment period. USCIS did not receive 

any comments for this information 

collection. 

The purpose of this notice is to allow 

an additional 30 days for public 

comments. Comments are encouraged 

and will be accepted until May 14, 

2012. This process is conducted in 

accordance with 5 CFR 1320.10. 

Written comments and/or suggestions 

regarding the item(s) contained in this 

notice, especially regarding the 

estimated public burden and associated 

response time, should be directed to the 

Department of Homeland Security 

(DHS), and to the Office of Information 

and Regulatory Affairs, Office of 

Management and Budget (OMB), USCIS 

Desk Officer. Comments may be 

submitted to: Chief, Regulatory 

Coordination Division, Office of Policy 

and Strategy, USCIS, DHS, 20 

Massachusetts Avenue NW., Suite 5012, 

Washington, DC 20529–2210. 

Comments may also be submitted to 

DHS via facsimile to 202–272–8352 or 

via email at 

USCISFRComment@dhs.gov, and to the 

OMB USCIS Desk Officer via facsimile 

at 202–395–6974 or via email at 

oira_submission@omb.eop.gov. 


pmangrum on DSK3VPTVN1PROD with NOTICES